Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...
A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using ...
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
On November 19, 2024, Ractigen Therapeutics announced that the FDA granted Orphan Drug Designation to its siRNA therapy RAG-21 for ALS targeting the FUS gene. Amyotrophic Lateral Sclerosis ...
Monepantel is under clinical development by Neurizon Therapeutics and currently in Phase II for Amyotrophic Lateral Sclerosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback